Skip to main content
Figure 2 | Cardiovascular Diabetology

Figure 2

From: Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

Figure 2

Absolute Benefit Increase (ABI) of Exenatide QW (ExQW) vs Sitagliptin. Forest plot depicts the ABI (%) ± 95% CI of ExQW vs sitagliptin. Data comparing ExQW to sitagliptin originate from DURATION-2 (filled circles) and DURATION-4 (open circles) studies. ABI = 0% indicates no benefit; ABI <0% indicates sitagliptin provides a benefit vs ExQW.

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840